115 results about "Human lymphocyte" patented technology

Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.

This invention reveals the beneficial use of vitamin E tocotrienols for inhibition of chlamydial infections. Chlamydial infection levels in mouse macrophages treated with tocotrienol were decreased >50%, with concomitant aberrant pathogen development. The number of large and small inclusions in tocotrienol-versus-control cells was decreased 3-fold and 2-fold, respectively. When treated with delta tocotrienol, Chlamydia in human lymphocytes was inhibited by at least 2.6-fold in 1.5 days. Dietary delta tocotrienol inhibited Chlamydia infection and persistence in hypercholesterolemic patients with a corresponding drop in LDL. These studies demonstrate that tocotrienol lowers cholesterol, thus preventing or diminishing the cholesterol hijacking by Chlamydia obligatory for its infectivity and replication. Therefore, hypolipidemic agents used to treat cardiovascular diseases, metabolic syndrome, and diabetes are used as monotherapies, or in combination with tocotrienol to treat Chlamydia.

A control composition, and method of preparing a control composition, that includes stabilized, mammalian granulocytes having altered physical properties so that the granulocytes function as a human lymphocyte analogs when used on an automated blood cell analyzer.

A method for obtaining agonist, antagonist and inverse agonist, to a given physiological receptor is disclosed. For the method, use is made of in silico design synthetic immunogens, which are caused to act in vitro on human lymphocyte-containing cell populations. A preferred receptor is human CD152, particularly the regions of CDRl, CDR2 and CDR3 that elicit antibodies serving as antagonist, inverse agonist and agonist, respectively. Also provided is a method in the treatment of human peripheral lymphocytes for use in the screening of CD152 ligands that yield pharmacological effects.

The invention discloses an antibody for resisting human CD79a extracellular terminal protein, a coding gene and application. The antibody is characterized in that a human B cell lymphoma Raji cell line is used as an immunogen for immunizing mice; splenocyte is obtained and then is fused with a mouse myeloma cell to obtain a hybridoma cell; a monoclonal antibody for specifically aiming at the human CD79a extracellular terminal protein is obtained via screening; an amino acid sequence of the monoclonal antibody is obtained by sequence analysis; variable region sequence with a heavy chain and a light chain and CDR (Complementarity-Determining Region) sequences with light chains and heavy chains are obtained via analyzing; an chimeric antibody expressed via cloning can be used for effectively and specifically recognizing the human CD79a extracellular terminal protein; in addition, when the antibody acts on human B lymphocyte, the internalization rate is high; the antibody has a good prospect for preparing a targeted drug of targeted B lymphocyte and can be used for treating diseases associated with the B lymphocyte.

The present invention provides cell culture media and methods useful for determining levels of intracellular function of glutathione or cysteine and for providing biochemical analysis of antioxidant function in human lymphocytes.

The invention relates to a high efficiency fetal calf serum substitute. The high efficiency fetal calf serum substitute is composed of recombinant human albumin, recombinant human transferrin, galactose, lipid, a trace element compound and vitamins, a weight ratio of the recombinant human albumin to the recombinant human transferrin to the galactose is 2:50:(15-25), and the lipid is a cholesterol, linoleic acid and linolenic acid mixture. The fetal calf serum substitute provided by the invention avoids infectious disease propagation risk and foreign protein induced allergy, increases the in vitro culture survival rate and the increment multiple of human lymphocytes to 96% and 28 respectively, improves the supply of the lymphocytes, reduces the culture cost, and facilitates large scale use.

The invention discloses a specific chimeric antigen receptor (anti-BCMA scFv-CD8a-41BB-CD3 zeta) for human BCMA and application thereof. The chimeric antigen receptor is formed by a single-chain-antibody anti-BCMA scFv, a hinge region, a transmembrane region and an intracellular region in series. The chimeric antigen receptor is used for modifying human T lymphocyte, and the modified T lymphocyteis used for prevention and treatment of surface BCMA positive tumor and preparing of antitumor medicines.

The invention relates to a product for controlling the quality of lyophilized human lymphocyte surface antigens, which is a grey-white solid prepared by lyophilizing a cell suspension having a cell concentration of 400,000-600,000/mL and containing lyophilized human lymphocytes immobilized by a neutral buffer formaldehyde solution and a protective agent. The mark values respectively are: CD<3> of 37.25-69.1%, CD<4> of 17.9-33.7%, CD<8> of 12.4-23.9%, and the ratio of CD<4>/CD<8> of 0.98-1.94. The invention also provides the preparation method of the quality control product. The product has the characteristics of good antigen storability and stable antigenicity, and can be used for the quality control reagent for detecting the lymphocyte surface mark antigenicity (CD series) by adopting the cell analyzer method, the immunofluorescence method, the immunoenzyme method, a SPA (Staphylococcus aureus A protein) rosettes method and the like.

The invention relates to the field of biology and discloses a placental hematopoietic stem cell and a preparation method thereof and a placental hematopoietic stem cell injection. The preparation method comprises the following steps of: after pretreating a placenta, digesting the treated placenta by using collagenase type IV digestive juice and collagenase type II digestive juice, then washing and filtering and respectively collecting first filtrate and first residue; digesting the first filter residue by using collagenase type I digestive juice and the collagenase type II digestive juice in the first step and then washing, filtering and collecting second filtrate; combining the filtrate from two times, centrifuging and discarding supernate, re-suspending and precipitating; adding a resuspension solution into a lymphocytes separation medium; and carrying out density gradient centrifugation, collecting a buffy coat cell solution on an intermediate layer and centrifuging and discarding supernate to obtain the placental hematopoietic stem cell. According to the placental hematopoietic stem cell and the preparation method thereof disclosed by the invention, collagenase type IV and collagenase type II are combined, collagenase type I and collagenase type II are combined and the hematopoietic stem cell is prepared by fully digesting the placenta according to the characteristics of different collagenases, so that the quantity and the vitality of the prepared hematopoietic stem cell are improved.

The invention provides a nucleic acid which can be expressed on a CD20 chimeric antigen receptor of the surface of a human lymphocyte and a tag fusion protein in a coded manner. The chimeric antigen receptor comprises an extracellular binding region, a transmembrane domain and an intracellular signal region which are connected sequentially and a tag protein which can be used for detecting CAR-T cells in a tracking manner, wherein the extracellular binding region comprises a single-chain antibody scFv(CD20) of the CD20 extracellular region specifically; and the nucleic acid also expresses a protein capable of inducing apoptosis in the human lymphocyte in a coding manner, the chimeric antigen receptor modified T lymphocyte apoptosis can be induced at any time, and side effects after immunotherapy are eliminated. The invention further provides T lymphocyte modified by protein expressed by the nucleic acid, the chimeric antigen receptor which can be directly detected is expressed on the surface, and the protein capable of inducing apoptosis is expressed intracellularly.

The invention relates to the technical field of biology, in particular to a method for preparing dendritic cell vaccine. The method is characterized by comprising the following preparation steps: (1) taking autologous blood of a patient, and separating red blood cells, mononuclear cells and plasma from separating medium of human lymphocyte; (2) adjusting concentration of the mononuclear cells; (3) adding the solution into a six-pore plate and performing adherence for 16 hours; (4) sucking and discharging non-adherent cells on the upper layer of each pore of the six-pore plate; (5) adding 3ml of dendritic cell (DC) culture medium, placing the solution in a carbon dioxide cultivating box with the concentration of carbon dioxide of 5% at the temperature of 37 DEG C to perform cultivation for 2-3 days; (6) performing half-quantity liquid changing; (7) enabling the concentration of the autologous tumor antigen in each pore of the six-pore plate to be 20 mu g/ml by loading the autologous tumor antigen in the sixth day; and (8) detecting the quantity and maturity of the matured DC cells after 24 hours. Compared with the prior art, the number of the matured DC cells at least reaches 1*107, and the maturity is larger than 85%.

The invention discloses a preparation method of leukocyte extract. Neonate cord blood is used directly as a raw material subjected to human lymphocyte separation density-gradient centrifugation to obtain PBMCs (peripheral blood mononuclear cells); amplification culture is performed via cord serum separated from the cord blood; centrifugal separating is performed to obtain supernate; leukocyte extract is acquired by ultra-filtration. The preparation method has no need for bovine serum, no heterogeneous animal proteins or stimulating factors are involved, and safety of application in human bodies is good. The leukocyte extract prepared via the method has rich natural human cellular factors, wherein bFGF (basic fibroblast growth factor) reaches 60 pg/ml and above, the yield is high, and the production cost is low. The invention also provides application of the leukocyte extract in the activation and restoration of cells. The leukocyte extract may be added to cosmetics to provide synergy with other components in cosmetic formulations; the leukocyte extract can cooperate to improve cell mitochondrial functionality, complete nutrients for cell metabolism are provided, and the cell activating function of the leukocyte extract is significantly improved.

The invention aims to provide a freeze-dried human lymphocyte CD4 surface antigen quality control material and a preparation method thereof. The reference substance is subjected to surface or intracellular specific antibody labeling by peripheral lymphocytes and can be applied to direct detection of flow cytometry. Moreover, in the preparation process of the reference substance, the concentrationof specific cells is calibrated after positive cell counting of the specific antigen, so the reference substance can provide reference for relative counting detection of the flow cytometry and can also serve as a reference substance or a counting reference in absolute counting detection, particularly applied to reference and calibration of flow cytometry calculated by a volumetric method at different time, different equipment and different personnel.

A recombinant plasmid vector containing human B lymphocyte stimulating factor (hBlyS) gene, the construction and expression of said expression vector, the process for preparing its monoclonal antibody and the application of said monoclonal antibody in preparing the medicines to treat B lymphocyte cancer and self-immunopathy and the test reagent for the BlyS concentration in human plasma are disclosed.